X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FULFORD INDIA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FULFORD INDIA GLENMARK PHARMA/
FULFORD INDIA
 
P/E (TTM) x 11.9 398.8 3.0% View Chart
P/BV x 3.1 6.2 50.7% View Chart
Dividend Yield % 0.4 0.1 452.9%  

Financials

 GLENMARK PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
FULFORD INDIA
Mar-14
GLENMARK PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs993942 105.4%   
Low Rs729450 162.1%   
Sales per share (Unadj.) Rs325.5691.4 47.1%  
Earnings per share (Unadj.) Rs39.311.5 342.8%  
Cash flow per share (Unadj.) Rs48.715.4 316.8%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.3 80.8%  
Book value per share (Unadj.) Rs159.2380.0 41.9%  
Shares outstanding (eoy) m282.173.90 7,235.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.0 262.8%   
Avg P/E ratio x21.960.7 36.1%  
P/CF ratio (eoy) x17.745.3 39.1%  
Price / Book Value ratio x5.41.8 295.3%  
Dividend payout %5.117.4 29.2%   
Avg Mkt Cap Rs m242,9912,714 8,951.9%   
No. of employees `00013.00.4 2,920.5%   
Total wages/salary Rs m16,408505 3,249.1%   
Avg. sales/employee Rs Th7,083.96,073.0 116.6%   
Avg. wages/employee Rs Th1,265.41,137.4 111.3%   
Avg. net profit/employee Rs Th855.1100.7 849.3%   
INCOME DATA
Net Sales Rs m91,8572,696 3,406.6%  
Other income Rs m374125 298.0%   
Total revenues Rs m92,2302,822 3,268.5%   
Gross profit Rs m20,367-46 -43,894.5%  
Depreciation Rs m2,64415 17,392.8%   
Interest Rs m2,37310 24,981.1%   
Profit before tax Rs m15,72454 28,957.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,82710 39,862.5%   
Profit after tax Rs m11,08845 24,804.3%  
Gross profit margin %22.2-1.7 -1,288.5%  
Effective tax rate %24.317.7 137.7%   
Net profit margin %12.11.7 728.1%  
BALANCE SHEET DATA
Current assets Rs m68,7461,738 3,954.8%   
Current liabilities Rs m27,027545 4,961.8%   
Net working cap to sales %45.444.3 102.6%  
Current ratio x2.53.2 79.7%  
Inventory Days Days8548 175.4%  
Debtors Days Days964 2,219.4%  
Net fixed assets Rs m24,13212 202,793.9%   
Share capital Rs m28239 723.6%   
"Free" reserves Rs m44,6431,443 3,093.8%   
Net worth Rs m44,9251,482 3,031.4%   
Long term debt Rs m45,3630-   
Total assets Rs m117,6392,077 5,664.7%  
Interest coverage x7.66.7 113.5%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.81.3 60.1%   
Return on assets %11.42.6 438.4%  
Return on equity %24.73.0 818.2%  
Return on capital %19.14.3 444.8%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m56,15217 326,462.8%   
Fx outflow Rs m8,084673 1,200.9%   
Net fx Rs m48,068-656 -7,327.8%   
CASH FLOW
From Operations Rs m6,57490 7,304.8%  
From Investments Rs m-7,124105 -6,810.2%  
From Financial Activity Rs m5,432-14 -38,521.3%  
Net Cashflow Rs m1,992181 1,103.8%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 3.8 181.6%  
FIIs % 34.4 0.1 34,400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.2 49.5%  
Shareholders   56,727 4,783 1,186.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS